|
1
|
Hirota S: Differential diagnosis of
gastrointestinal stromal tumor by histopathology and
immunohistochemistry. Transl Gastroenterol Hepatol. 3:272018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coffey RJ, Washington MK, Corless CL and
Heinrich MC: Ménétrier disease and gastrointestinal stromal tumors:
Hyperproliferative disorders of the stomach. J Clin Invest.
117:70–80. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Su WC, Tsai HL, Yeh YS, Huang CW, Ma CJ,
Chen CY, Chang TK and Wang JY: Combined computed
tomography-measured tumor density and RECIST for evaluating
neoadjuvant therapy in locally advanced gastrointestinal stromal
tumors. Transl Cancer Res. 7:634–644. 2018. View Article : Google Scholar
|
|
4
|
Rodrigues J, Campanati RG, Nolasco F,
Bernardes AM, Sanches SRA and Savassi-Rocha PR: Pre-operative
gastric gist downsizing: The importance of neoadjuvant therapy. Arq
Bras Cir Dig. 32:e14272019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Mehren M and Joensuu H:
Gastrointestinal stromal tumors. J Clin Oncol. 36:136–143. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Z, Zhang Z, Sun J, Li J, Zeng Z, Ma M,
Ye X, Feng F and Kang W: Comparison of prognosis between
neoadjuvant imatinib and upfront surgery for GIST: A systematic
review and meta-analysis. Front Pharmacol. 13:9664862022.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Casali PG, Jost L, Reichardt P, Schlemmer
M and Blay JY: Gastrointestinal stromal tumours: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
20 (Suppl):S64–S67. 2009. View Article : Google Scholar
|
|
8
|
Wang D, Zhang Q, Blanke CD, Demetri GD,
Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M
and Eisenberg BL: Phase II trial of neoadjuvant/adjuvant imatinib
mesylate for advanced primary and metastatic/recurrent operable
gastrointestinal stromal tumors: Long-term follow-up results of
radiation therapy oncology group 0132. Ann Surg Oncol.
19:1074–1080. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Joensuu H: Gastrointestinal stromal tumor
(GIST). Ann Oncol. 17 (Suppl 10):x280–x286. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Patel SR and Reichardt P: An updated
review of the treatment landscape for advanced gastrointestinal
stromal tumors. Cancer. 127:2187–2195. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bauer S, George S, von Mehren M and
Heinrich MC: Early and next-generation KIT/PDGFRA kinase inhibitors
and the future of treatment for advanced gastrointestinal stromal
tumor. Front Oncol. 11:6725002021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding P, Wu J, Wu H, Sun C, Guo H, Lowe S,
Yang P, Tian Y, Liu Y, Meng L and Zhao Q: Inflammation and
nutritional status indicators as prognostic indicators for patients
with locally advanced gastrointestinal stromal tumors treated with
neoadjuvant imatinib. BMC Gastroenterol. 23:232023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Yin Y, Shen C, Yin X, Cai Z, Pu L,
Fu W, Wang Y and Zhang B: Preoperative imatinib treatment in
patients with locally advanced and metastatic/recurrent
gastrointestinal stromal tumors: A single-center analysis. Medicine
(Baltimore). 99:e192752020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vassos N, Jakob J, Kähler G, Reichardt P,
Marx A, Dimitrakopoulou-Strauss A, Rathmann N, Wardelmann E and
Hohenberger P: Preservation of organ function in locally advanced
non-metastatic gastrointestinal stromal tumors (GIST) of the
stomach by neoadjuvant imatinib therapy. Cancers (Basel).
13:5862021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
organization for research and treatment of cancer, national cancer
institute of the United States, national cancer institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tsai HL, Shi HY, Chen YC, Huang CW, Su WC,
Chang TK, Li CC, Chen PJ, Yeh YS, Yin TC and Wang JY: Clinical and
cost-effectiveness analysis of mFOLOFX6 with or without a targeted
drug among patients with metastatic colorectal cancer: Inverse
probability of treatment weighting. Am J Cancer Res. 13:4039–4056.
2023.PubMed/NCBI
|
|
17
|
Hsiao HH, Liu YC, Tsai HJ, Chen LT, Lee
CP, Chuan CH, Wang JY, Yang SF, Tseng YT and Lin SF: Imatinib
mesylate therapy in advanced gastrointestinal stromal tumors:
Experience from a single institute. Kaohsiung J Med Sci.
22:599–603. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van Oosterom AT, Judson I, Verweij J,
Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A,
Sciot R, Van Glabbeke M, et al: Safety and efficacy of imatinib
(STI571) in metastatic gastrointestinal stromal tumours: A phase I
study. Lancet. 358:1421–1423. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Demetri GD, von Mehren M, Blanke CD, Van
den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA,
Singer S, Janicek M, et al: Efficacy and safety of imatinib
mesylate in advanced gastrointestinal stromal tumors. N Engl J Med.
347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blanke CD, Rankin C, Demetri GD, Ryan CW,
von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki
RG, et al: Phase III randomized, intergroup trial assessing
imatinib mesylate at two dose levels in patients with unresectable
or metastatic gastrointestinal stromal tumors expressing the kit
receptor tyrosine kinase: S0033. J Clin Oncol. 26:626–632. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seshadri RA and Rajendranath R:
Neoadjuvant imatinib in locally advanced gastrointestinal stromal
tumors. J Cancer Res Ther. 5:267–271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van der Burg SJC, van de Wal D, Roets E,
Steeghs N, van Sandick JW, Kerst M, van Coevorden F, Hartemink KJ,
Veenhof XAAFA, Koenen AM, et al: Neoadjuvant imatinib in locally
advanced gastrointestinal stromal tumors (GISTs) is effective and
safe: Results from a prospective single-center study with 108
Patients. Ann Surg Oncol. 30:8660–8668. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lam TJR, Udonwa SA, Masuda Y, Yeo MHX,
Farid Bin Harunal Ras M and Goh BKP: A systematic review and
meta-analysis of neoadjuvant imatinib use in locally advanced and
metastatic gastrointestinal stromal tumors. World J Surg.
48:1681–1691. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khosroyani HM, Klug LR and Heinrich MC:
TKI treatment sequencing in advanced gastrointestinal stromal
tumors. Drugs. 83:55–73. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee JH, Kim Y, Choi JW and Kim YS:
Correlation of imatinib resistance with the mutational status of
KIT and PDGFRA genes in gastrointestinal stromal tumors: A
meta-analysis. J Gastrointestin Liver Dis. 22:413–418.
2013.PubMed/NCBI
|
|
26
|
Li W, Li X, Yu K, Xiao B, Peng J, Zhang R,
Zhang L, Wang K, Pan Z, Li C and Wu X: Efficacy and safety of
neoadjuvant imatinib therapy for patients with locally advanced
rectal gastrointestinal stromal tumors: A multi-center cohort
study. Front Pharmacol. 13:9501012022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
von Mehren M, Randall RL, Benjamin RS,
Boles S, Bui MM, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane
JM, et al: Soft tissue sarcoma, version 2.2018, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
16:536–563. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang SY, Wu CE, Lai CC, Chen JS, Tsai CY,
Cheng CT, Yeh TS and Yeh CN: Prospective evaluation of neoadjuvant
imatinib use in locally advanced gastrointestinal stromal tumors:
Emphasis on the optimal duration of neoadjuvant imatinib use,
safety, and oncological outcome. Cancers (Basel). 11:4242019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Iwatsuki M, Harada K, Iwagami S, Eto K,
Ishimoto T, Baba Y, Yoshida N, Ajani JA and Baba H: Neoadjuvant and
adjuvant therapy for gastrointestinal stromal tumors. Ann
Gastroenterol Surg. 3:43–49. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mohammadi M, NS IJ, Hollander DD, Bleckman
RF, Oosten AW, Desar IME, Reyners AKL, Steeghs N and Gelderblom H:
Improved efficacy of first-line imatinib in advanced
gastrointestinal stromal tumors (GIST): The Dutch gist registry
data. Target Oncol. 18:415–423. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Medrano Guzman R, Lopez Lara X, Arias
Rivera AS, Garcia Rios LE and Brener Chaoul M: Neoadjuvant imatinib
in gastrointestinal stromal tumors (GIST): The first analysis of a
Mexican population. Cureus. 16:e650012024.PubMed/NCBI
|
